PsyBio Therapeutics Corp. (PSYBF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PsyBio Therapeutics Corp. (PSYBF) trades at $0.00001 with AI Score 45/100 (Grade C). PsyBio Therapeutics Corp. is a biotechnology company focused on developing psychedelic-inspired medicines for mental health disorders. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for PSYBF: PSYBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PSYBF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PSYBF: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
PsyBio Therapeutics Corp. (PSYBF) Healthcare & Pipeline Overview
PsyBio Therapeutics Corp. is a biotechnology firm specializing in the research, development, and commercialization of psychedelic-inspired medicines targeting mental health disorders, operating within the high-growth, yet nascent, psychedelic therapeutics market, and currently based in the United States.
What Is the Investment Thesis for PSYBF?
PsyBio Therapeutics Corp. presents a high-risk, high-reward investment opportunity within the emerging psychedelic medicine market. The company's focus on developing novel treatments for mental health disorders aligns with a growing need for innovative therapies. However, the company's early stage of development and reliance on future funding introduce significant uncertainty. Key value drivers include successful preclinical and clinical trial outcomes, strategic partnerships, and regulatory approvals. The company's small market capitalization and limited financial resources necessitate careful monitoring of cash burn and potential dilution. The investment thesis hinges on PsyBio's ability to navigate the complex regulatory landscape and demonstrate the efficacy and safety of its psychedelic-inspired medicines.
Based on FMP financials and quantitative analysis
PSYBF Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- A P/E ratio of -0.00 reflects the company's current lack of profitability, typical for early-stage biotechnology firms.
- Beta of 0.27 suggests the stock is significantly less volatile than the overall market.
- The company's focus on psychedelic-inspired medicines positions it in a high-growth, albeit nascent, market segment.
- Headquartered in the United States, providing access to a large pharmaceutical market and established regulatory pathways.
Who Are PSYBF's Competitors?
PSYBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACHFF Arch Biopartners Inc. | $0.71 | -10.69% | $48.2M | 38 |
| CVALF Covalon Technologies Ltd. | $1.71 | +4.27% | $47.2M | 44 |
| HBPCF Helix BioPharma Corp. | $1.71 | +0.00% | $131M | 45 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PSYBF's Key Strengths?
Focus on the emerging market of psychedelic-inspired medicines.
- Potential for breakthrough therapies for mental health disorders.
- Proprietary formulations and intellectual property.
- Experienced management team.
What Are PSYBF's Weaknesses?
Early stage of development with limited financial resources.
- High regulatory hurdles and lengthy clinical trials.
- Dependence on future funding and partnerships.
- Small number of employees.
What Could Drive PSYBF Stock Higher?
Announcement of preclinical trial results for lead drug candidate.
- Potential partnership or licensing agreement with a pharmaceutical company.
- Advancements in research and development of psychedelic-inspired medicines.
- Increasing awareness and acceptance of psychedelic medicine.
- Regulatory developments and potential changes in drug policy.
What Are the Key Risks for PSYBF?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Negative clinical trial results for drug candidates.
- Regulatory setbacks and delays in drug approval process.
- Competition from established pharmaceutical companies.
- Dependence on future funding and partnerships.
- Negative public perception of psychedelic drugs.
What Are the Growth Opportunities for PSYBF?
- Expansion into new therapeutic areas: PsyBio can explore the application of its psychedelic-inspired medicines to treat a broader range of mental health disorders, such as anxiety, PTSD, and addiction. The market for mental health treatments is substantial, with an estimated global value of $100 billion. Successful expansion into new indications could significantly increase PsyBio's revenue potential and market share. This strategy depends on positive clinical trial results and regulatory approvals, with a timeline of 3-5 years.
- Strategic partnerships with pharmaceutical companies: Collaborating with larger pharmaceutical companies can provide PsyBio with access to funding, expertise, and distribution channels. The pharmaceutical industry is actively seeking innovative therapies, and partnerships with biotech firms are common. A successful partnership could accelerate the development and commercialization of PsyBio's products. The timeline for securing a strategic partnership is uncertain but could occur within the next 1-2 years.
- Development of proprietary drug delivery systems: PsyBio can focus on developing innovative drug delivery systems to improve the efficacy and safety of its psychedelic-inspired medicines. This could involve developing formulations that enhance bioavailability, reduce side effects, or provide targeted drug delivery. The market for drug delivery technologies is growing, driven by the need for more effective and patient-friendly treatments. This strategy could provide PsyBio with a competitive advantage and increase the value of its products. The timeline for developing and implementing new drug delivery systems is 2-4 years.
- Securing regulatory approvals for its drug candidates: Obtaining regulatory approvals from the FDA is critical for PsyBio's success. The regulatory process for psychedelic-inspired medicines is complex and requires extensive clinical trial data. Successful navigation of the regulatory landscape and timely approval of its drug candidates will be essential for PsyBio to generate revenue and achieve profitability. The timeline for regulatory approvals is highly variable and depends on the specific drug candidate and clinical trial outcomes, but typically takes 3-7 years.
- Expansion into international markets: PsyBio can explore opportunities to expand its operations into international markets, such as Europe and Asia. These markets offer significant growth potential, driven by increasing awareness of mental health disorders and the availability of government funding for research and development. Successful expansion into international markets could diversify PsyBio's revenue streams and reduce its reliance on the US market. The timeline for international expansion is 2-5 years and depends on regulatory approvals and market access agreements.
What Threats Does PSYBF Face?
- Competition from established pharmaceutical companies.
- Regulatory challenges and changing regulations.
- Negative public perception of psychedelic drugs.
- Potential for adverse side effects and safety concerns.
What Are PSYBF's Competitive Advantages?
- Proprietary formulations of psychedelic-inspired medicines.
- Intellectual property protection through patents and trademarks.
- Early mover advantage in the emerging psychedelic medicine market.
What Does PSYBF Do?
PsyBio Therapeutics Corp. is a biotechnology company dedicated to the research, development, and potential commercialization of psychedelic-inspired regulated medicines. These medicines are intended for the treatment of various mental health and other disorders. Headquartered in Coconut Creek, Florida, the company is focused on addressing unmet needs in the mental health space through innovative therapeutic approaches. PsyBio's strategy involves leveraging the potential of psychedelic compounds to create novel treatments for conditions such as depression, anxiety, and PTSD. The company is in the early stages of its development, concentrating on research and preclinical studies to advance its pipeline of drug candidates. PsyBio's focus is on developing proprietary formulations and delivery methods to enhance the efficacy and safety of its psychedelic-inspired medicines. As a relatively new entrant in the biotechnology sector, PsyBio is navigating the regulatory landscape and scientific challenges associated with psychedelic drug development. The company's success will depend on its ability to secure funding, advance its research programs, and obtain regulatory approvals for its products.
What Products and Services Does PSYBF Offer?
- Researches psychedelic-inspired medicines.
- Develops regulated medicines for mental health disorders.
- Aims to commercialize its developed medicines.
- Focuses on treatments for conditions like depression and anxiety.
- Conducts preclinical and clinical studies.
- Seeks to create novel therapeutic approaches.
How Does PSYBF Make Money?
- Focuses on research and development of psychedelic-inspired medicines.
- Aims to generate revenue through commercialization of approved drugs.
- May seek partnerships or licensing agreements with larger pharmaceutical companies.
What Industry Does PSYBF Operate In?
PsyBio Therapeutics Corp. operates within the biotechnology industry, specifically targeting the emerging market for psychedelic-inspired medicines. This market is driven by increasing awareness of mental health disorders and the limitations of existing treatments. The competitive landscape includes both established pharmaceutical companies and smaller biotech firms exploring psychedelic compounds. The industry is characterized by high regulatory hurdles, lengthy clinical trials, and significant investment in research and development. The growth potential is substantial, driven by the potential for breakthrough therapies and increasing acceptance of psychedelic medicine.
Who Are PSYBF's Key Customers?
- Patients suffering from mental health disorders.
- Healthcare providers who prescribe medications.
- Pharmaceutical companies interested in licensing or acquiring new drugs.
Company Profile
PsyBio Therapeutics Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Denver, US. The company is led by CEO Evan Levine. PSYBF has traded publicly since 2021.
PsyBio Therapeutics Corp. (PSYBF) Valuation Context
Relative to its peer group, PSYBF's quantitative score of 45/100 is below the peer average of 56/100.
Financial Health
PsyBio Therapeutics Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
PSYBF Financials
Bull Case vs Bear Case
Bull Case
- Focus on the emerging market of psychedelic-inspired medicines.
- Potential for breakthrough therapies for mental health disorders.
- Proprietary formulations and intellectual property.
- Experienced management team.
Bear Case
- Early stage of development with limited financial resources.
- High regulatory hurdles and lengthy clinical trials.
- Dependence on future funding and partnerships.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PSYBF Latest News
No recent news available for PSYBF.
PSYBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PSYBF.
Price Targets
Wall Street price target analysis for PSYBF.
PSYBF MoonshotScore
What does this score mean?
The MoonshotScore rates PSYBF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Evan Mike Levine
CEO
Evan Mike Levine serves as the CEO of PsyBio Therapeutics Corp. His background includes experience in managing companies, though specific details on his prior roles and educational qualifications are not provided. As CEO, he is responsible for leading the strategic direction of the company, overseeing research and development activities, and securing funding to advance PsyBio's pipeline of psychedelic-inspired medicines. His leadership is crucial for navigating the complex regulatory landscape and building partnerships within the biotechnology industry.
Track Record: Due to limited information, it is difficult to assess Evan Mike Levine's specific track record at PsyBio Therapeutics Corp. However, his leadership is essential for guiding the company through its early stages of development, securing funding, and advancing its research programs. Success will be measured by the company's ability to achieve key milestones, such as positive clinical trial results and regulatory approvals.
PSYBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that PsyBio Therapeutics Corp. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies on the OTC Other tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is generally associated with higher risk due to the potential for less transparency and greater price volatility. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume on the OTC market.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight and transparency.
- Higher risk of financial distress or bankruptcy.
- Limited access to capital markets.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Determine the company's capital structure and debt levels.
- Understand the company's regulatory environment and compliance requirements.
- Consult with a financial advisor or legal professional.
- Company is registered and in good standing with the relevant regulatory authorities.
- Company has a clear business plan and strategy.
- Company has a qualified management team with relevant experience.
- Company has secured funding from reputable investors.
- Company has a valid website and contact information.
Common Questions About PSYBF (Healthcare)
What does the AI Score mean for PSYBF?
PSYBF holds an AI Score of 45/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. PsyBio Therapeutics Corp. is a biotechnology company focused on developing psychedelic-inspired medicines for mental health disorders. The company is in the early stages of research, development …
What does PsyBio Therapeutics Corp. do?
PsyBio Therapeutics Corp. is a biotechnology company focused on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders. The company aims to address unmet needs in the mental health space by developing novel therapeutic approaches using psychedelic compounds.
What do analysts say about PSYBF stock?
As of March 17, 2026, there is no readily available analyst coverage for PSYBF stock due to its OTC listing and small market capitalization. Consequently, there is no consensus rating or price target. Investors should conduct their own thorough research and consider the risks associated with investing in early-stage biotechnology companies operating in the emerging psychedelic medicine market.
What are the main risks for PSYBF?
The main risks for PsyBio Therapeutics Corp. include the inherent uncertainties of drug development, such as negative clinical trial results and regulatory setbacks. As an early-stage biotechnology company, PsyBio is heavily reliant on securing future funding and partnerships to advance its research programs.
What are the key factors to evaluate for PSYBF?
PsyBio Therapeutics Corp. (PSYBF) holds an AI score of 45/100 (low). presents a high-risk, high-reward investment opportunity within the emerging psychedelic medicine market. Not financial advice.
How frequently does PSYBF data refresh on this page?
PSYBF's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PSYBF's recent stock price performance?
PsyBio Therapeutics Corp. (PSYBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on the emerging market of psychedelic-inspired medicines. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PSYBF overvalued or undervalued right now?
PsyBio Therapeutics Corp. (PSYBF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PSYBF before investing?
Before investing in PsyBio Therapeutics Corp. (PSYBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC listing and early stage of development.
- Financial data may not be readily available or up-to-date.